Lundbeckfonden Ventures News

Lundbeckfond Ventures is LFÍ Life Science Investments new name
Syntaxin, a biotechnology company developing novel biopharmaceuticals to control cell secretion, announces it has successfully raised £18 million in new funding
Mette Kirstine Agger appointed Head of LFI Life Science Investments
1 63 64 65

Lundbeckfonden Ventures


Sanifit Enhances Leadership Team with New Executive Appointments
2. June 2020
Acacia Pharma Group PLC – Acacia Pharma Announces Debt for Equity Swap with Cosmo Pharmaceuticals
2. June 2020
Acacia Pharma Group PLC – Issue of Equity on Exercise of Options/Vesting of Performance Share Awards
8. May 2020